BACE2 and Alzheimer disease: Similar results were obtained with the BACE inhibitor verubecestat, which was clinically tested for treatment of AD (Figure 3, C and D), and with C3 (BACE inhibitor IV) (Supplemental Figure 6, A and B), which preferentially inhibits BACE1 but also partly inhibits BACE2 (16, 19).